Your session is about to expire
← Back to Search
CPX-351 for Acute Myeloid Leukemia
Study Summary
This trial is testing how well CPX-351 works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 56 Patients • NCT02286726Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have AML that developed after cancer treatment.I have a liver condition like cirrhosis or hepatitis.I have a history of Wilson disease or similar conditions.I have been treated for acute myeloid leukemia before.I have active leukemia in my brain or spinal cord.I have received a high dose of a specific chemotherapy drug.I have a current infection that isn't responding to treatment.My leukemia is caused by a core-binding factor.I have an active hepatitis B or C infection.My AML developed from a previous MDS or CMML condition.I have severe heart issues, including recent heart attacks or unstable chest pain.I have been diagnosed with acute promyelocytic leukemia.You are currently pregnant or breastfeeding.My leukemia is AML with changes related to MDS.I have an active HIV infection.I can take care of myself and am up and about more than half of my waking hours.I will use a latex condom during sex with women who can become pregnant.I have another cancer that is not under control.
- Group 1: Treatment (CPX-351)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients being sought for this clinical trial at this time?
"The clinical trial is still recruiting patients, as seen on clinicaltrials.gov. This research was initially posted on 7/29/2021 and updated for the last time on 5/5/2022."
To be eligible for this research, what are the requirements?
"This leukemia study has room for 46 participants that are myeloid, between 18-59 years old."
Does this research study have an age limit?
"This trial includes a patient population that is between 18-59 years old."
Has the FDA given their okay to Liposome-encapsulated Daunorubicin-Cytarabine?
"While there is some evidence of Liposome-encapsulated Daunorubicin-Cytarabine's safety, as this is a Phase 2 trial, no efficacy data exists yet."
What other similar medical experiments have been conducted with Liposome-encapsulated Daunorubicin-Cytarabine?
"There are a total of 276 clinical trials still active for Liposome-encapsulated Daunorubicin-Cytarabine, with 67 of those being in Phase 3. The majority taking place New york City, though there are 12,438 locations conducting these trials globally."
What condition does Liposome-encapsulated Daunorubicin-Cytarabine target?
"Liposome-encapsulated Daunorubicin-Cytarabine is most commonly used to treat leukemia, myelocytic, and acute conditions. However, it can also be taken for multiple other conditions like blast phase chronic myelocytic leukemia, lymphoma, and prophylaxis of meningeal leukemia."
How many people are willing to participate in this experiment?
"In order to successfully run this trial, 46 patients that meet the specific inclusion criteria are required. The sponsor, Jazz Pharmaceuticals, will be conducting the trial at different sites including Allegheny Health Network Cancer Institute - West Penn Hospital in Pittsburgh, Pennsylvania and University of Nebraska Medical Center in Omaha, Nebraska."
Share this study with friends
Copy Link
Messenger